Pierre Fabre Pharmaceuticals and Addex Sign Early-Stage Agreement
Complete the form below to unlock access to ALL audio articles.
Addex Therapeutics has announced that it has granted an option to license its metabotropic glutamate receptor subtype 3 (“mGlu3 receptor”) program to Pierre Fabre Pharmaceuticals, a laboratory with a proven track-record in discovering, developing and marketing products in the field of Central Nervous System (CNS).
“This agreement confirms our strong and continued interest in the CNS field to develop therapies addressing critical global health problems”, commented Laurent Audoly, Head of Pierre Fabre Pharmaceuticals R&D, “Pierre Fabre is committed to developing such early stage collaborations to capitalize on its long-standing preclinical and clinical experience in the CNS field to create value and win-win scenarios with our partners.”
“We are enthusiastic to initiate this collaboration with Addex, one of the world's leaders in allosteric modulator drug discovery”, said Alexander Scheer, Associate Research Director at Pierre Fabre Pharmaceuticals. “Addex allosteric modulator discovery platform has demonstrated its unique capabilities to discover innovative first in class compounds.”
“We are delighted to be working with Pierre Fabre and their CNS discovery group which has a strong track record in CNS drug discovery,” said Robert Lütjens, Head of Discovery of Addex. “mGlu3 receptor represents an exciting novel target and we look forward to rapidly advancing this program.”
“This agreement represents a strong validation of our discovery platform and highlights the value of Addex' proprietary expertise in allosteric modulator drug discovery," said Tim Dyer, CEO of Addex. “This agreement is another example of our strategy to advance our preclinical programs through collaboration with industry.”
Using its proprietary allosteric modulator discovery platform, Addex has been able to identify unique mGlu3 receptor positive and negative allosteric modulators. These compounds, although still at an early stage, represent excellent starting points for chemical optimization, and have a great potential to become first-in-class molecules useful for the treatment of CNS disorders involving an imbalance in mGlu3 receptor signalling.
Under the terms of the agreement, Pierre Fabre will conduct chemistry, pharmacology and ADME, while Addex will support the project with its proprietary in vitro pharmacological assay platform. Financial terms of the agreement have not been disclosed.
